ReviewCellular & molecular immunology2014
The immunogenicity of cells derived from induced pluripotent stem cells.
Review in Cellular & molecular immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Mesenchymal stem cell therapy for end-stage liver disease: adversity and opportunity.Stem cell research & therapy · 2025Review
- CD9-enriched extracellular vesicles from chemically reprogrammed basal progenitors of salivary glands mitigate salivary gland fibrosis.Bioactive materials · 2025Article
- Human Umbilical Cord-Mesenchymal Stem Cells Combined With Low Dosage Nintedanib Rather Than Using Alone Mitigates Pulmonary Fibrosis in Mice.Stem cells international · 2025Article
- Development of a baculoviral CRISPR/Cas9 vector system for beta-2-microglobulin knockout in human pluripotent stem cells.Molecular genetics and genomics : MGG · 2024Article
- Advancements in neuroregenerative and neuroprotective therapies for traumatic spinal cord injury.Frontiers in neuroscience · 2024Review
- New treatment methods for myocardial infarction.Frontiers in cardiovascular medicine · 2023Review
- Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for Spinal Cord Injury.Cells · 2022Review
- Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022Review
- Etched 3D-Printed Polycaprolactone Constructs Functionalized with Reduced Graphene Oxide for Enhanced Attachment of Dental Pulp-Derived Stem Cells.Pharmaceutics · 2021Article
- Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product.Stem cells translational medicine · 2021Review
- Adult Stem Cells for Bone Regeneration and Repair.Frontiers in cell and developmental biology · 2019Review
- [Research progress on the donor cell sources of pancreatic islet transplantation for treatment of diabetes mellitus].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2018Review
- Autologous stem cell therapy for inherited and acquired retinal disease.Regenerative medicine · 2018Review
- Isolation, Culture, and Functional Characterization of Human Embryonic Stem Cells: Current Trends and Challenges.Stem cells international · 2018Review
- A Comparative Study of Three Different Types of Stem Cells for Treatment of Rat Spinal Cord Injury.Cell transplantation · 2017Article
- Primary Salivary Human Stem/Progenitor Cells Undergo Microenvironment-Driven Acinar-Like Differentiation in Hyaluronate Hydrogel Culture.Stem cells translational medicine · 2017Article
- Isolation, expansion and neural differentiation of stem cells from human plucked hair: a further step towards autologous nerve recovery.Cytotechnology · 2016Article
- CMI: Highlights in last three years.Cellular & molecular immunology · 2016Article
- Tissue Engineering and Regenerative Medicine 2015: A Year in Review.Tissue engineering. Part B, Reviews · 2016Review
- iPS cell transplantation for traumatic spinal cord injury.Current stem cell research & therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With their ability to undergo unlimited self-renewal in culture and to differentiate into all cell types in the body, human embryonic stem cells (hESCs) hold great potential for the treatment of currently incurable diseases. Two hESC-based cell therapies for spinal cord injury and macular degeneration have been advanced into human clinical trials. Despite this rapid progress, one key challenge of hESC-based cell therapy is the allogeneic immune rejection of hESC-derived cells by recipients. This problem could be mitigated by a recent breakthrough in the technology of induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient-specific somatic cells with defined factors, which could become a renewable source of autologous cells for cell therapy. However, recent studies revealing the abnormal epigenetics, genomic stability and immunogenicity of iPSCs have raised safety concerns over iPSC-based therapy. Recent findings related to the immunogenicity of iPSC derivatives will be summarized in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.